Sagimet BiosciencesSGMT
SGMT
About: Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Employees: 10
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
5.9% less ownership
Funds ownership: 69.97% [Q2] → 64.07% (-5.9%) [Q3]
23% less funds holding
Funds holding: 82 [Q2] → 63 (-19) [Q3]
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
25% less capital invested
Capital invested by funds: $72.7M [Q2] → $54.4M (-$18.4M) [Q3]
60% less call options, than puts
Call options by funds: $206K | Put options by funds: $515K
63% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 30
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
142%
upside
Avg. target
$25
398%
upside
High target
$32
546%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Oppenheimer Jay Olson 20% 1-year accuracy 20 / 102 met price target | 506%upside $30 | Outperform Initiated | 6 Dec 2024 |
HC Wainwright & Co. Ed Arce 54% 1-year accuracy 79 / 146 met price target | 546%upside $32 | Buy Reiterated | 15 Nov 2024 |
UBS Eliana Merle 20% 1-year accuracy 3 / 15 met price target | 142%upside $12 | Buy Initiated | 12 Nov 2024 |
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
Sagimet: More Than Just A MASH Drug Development Biotech
Sagimet Biosciences Inc.'s Initiation of the phase 3 FASCINIT and FASCINATE-3 studies, using denifanstat for treatment of patients with MASH/MAFLD & MASH respectively, expected before the end of 2024. The global acne treatment market size is projected to grow from $17.48 billion by 2032. Results from phase 3 study by partner Ascletis, using denifanstat for treatment of patients with Acne Vulgaris, expected by Q2 of 2025.
Neutral
PRNewsWire
1 month ago
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expected in the second quarter 2025 HANGZHOU, China , Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat) o nce-daily oral tablet for treatment of moderate to severe acne. The first patient was enrolled on January 24, 2024.
Positive
Seeking Alpha
2 months ago
Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Sagimet Biosciences' Denifanstat shows significant potential in treating MASH, with FDA Breakthrough Therapy designation and peer-reviewed validation, supporting a "Strong Buy" rating. Denifanstat's unique FASN inhibition mechanism effectively reduces liver fibrosis, positioning it as a superior treatment for advanced MASH compared to competitors like Tirzepatide. SGMT's robust financials, including $188.5 million in liquidity and no debt, provide a solid foundation for advancing Denifanstat through Phase 3 trials.
Neutral
GlobeNewsWire
2 months ago
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
- Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis - - Results support advancement of denifanstat into Phase 3 development -
Positive
Zacks Investment Research
2 months ago
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug
FDA's breakthrough therapy designation for SGMT's denifanstat for MASH with moderate-to-advanced liver fibrosis is based on phase IIb FASCINATE-2 study data.
Neutral
GlobeNewsWire
2 months ago
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
Supported by positive data from Phase 2b FASCINATE-2 trial of denifanstat in patients with MASH Preparations are ongoing to initiate Phase 3 program for denifanstat by the end of 2024 SAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to denifanstat for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
Neutral
GlobeNewsWire
2 months ago
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a virtual fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference at 2:30 PM ET on Monday, October 7, 2024.
Neutral
GlobeNewsWire
3 months ago
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
SAN MATEO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation highlighting denifanstat's anti-fibrotic activity in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the 8th Annual MASH Drug Development Summit being held in Boston on September 24-26, 2024.
Positive
24/7 Wall Street
4 months ago
3 Penny Stocks with 190% Growth Potential According to Wall Street Analysts
Penny stocks are a fascinating category of investment opportunities.
Neutral
GlobeNewsWire
4 months ago
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024.
Charts implemented using Lightweight Charts™